10/4/2021 8:37:24 AM
FDA Confirms Relmada Not Required To Conduct Two-Year Carcinogenicity Study
7/27/2021 7:42:43 AM
Relmada Therapeutics Announces Top-Line Results Of Study Evaluating REL-1017 Vs Oxycodone For Abuse Potential
7/20/2021 8:17:01 AM
Relmada Therapeutics Announces Acquisition Of Commercial Rights To Psilocybin And Derivates Program From Arbormentis
5/26/2021 8:29:51 AM
Relmada Therapeutics To Present REL-1017 Clinical Data At 2021 ASCP Annual Meeting
4/27/2021 8:42:57 AM
Relmada Therapeutics To Present Data Related To REL-1017
4/1/2021 8:09:04 AM
Relmada Initiates Phase 3 Study Of REL-1017 As Adjunctive Treatment For Patients With Major Depressive Disorder
12/7/2020 8:47:48 AM
Relmada Therapeutics Unveils Initiation Of Phase 3 Program For REL-1017 As Adjunctive Treatment For MDD Patients
6/23/2020 8:34:30 AM
Relmada Therapeutics Announces Notice Of Allowance For Patent In Canada Covering REL-1017 For Psychiatric Symptoms
5/27/2020 8:11:25 AM
Relmada Therapeutics Says Outcome Of End-of-Phase 2 Meeting With FDA For REL-1017; Says Can Proceed To Phase 3
3/9/2020 8:32:12 AM
Relmada Therapeutics Appoints Thomas Wessel As EVP, Head Of Research And Development